Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19976777 | 0.87 | POLB (0.39) | POLBNAMPTMAPK1HPGDLMNA | |
| SCHEMBL19976784 | 0.83 | MAPK1 (0.38) | POLBNAMPTMAPK1 | |
| SCHEMBL19976739 | 0.83 | HPGD (0.37) | POLBMAPK1HPGDLMNA | |
| SCHEMBL19976909 | 0.82 | POLB (0.34) | POLBNAMPTMAPK1HPGDLMNA | |
| SCHEMBL19976740 | 0.81 | HPGD (0.39) | POLBMAPK1HPGDLMNA | |
| SCHEMBL19976737 | 0.80 | HPGD (0.35) | POLBMAPK1HPGDLMNA | |
| SCHEMBL19976851 | 0.80 | POLB (0.35) | POLBNAMPTMAPK1HPGDLMNA | |
| SCHEMBL19976944 | 0.80 | MAPK1 (0.36) | POLBNAMPTMAPK1HPGDLMNA | |
| SCHEMBL19976759 | 0.80 | LMNA (0.36) | POLBMAPK1HPGDLMNA | |
| SCHEMBL19362791 | 0.79 | RAB9A (0.39) | POLBNAMPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920012-B2 | Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |